Clinical Trial Update: Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating pacritinib in combination with low-dose decitabine for intermediate-high risk myelofibrosis and related myeloproliferative neoplasm/m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Chronic Myeloid Leukemia
• Juvenile Myelomonocytic Leukemia
• Myelodysplastic Syndromes
• Myelofibrosis
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasm

Drugs mentioned

• Decitabine (Decitabine)
• Pacritinib (pacritinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia | Phase 1 | Status: WITHDRAWN